A Phase 2/3 interventional study of Busulfan (BU) and Cyclophosphamide (CY) in Autologous Hematopoietic Stem Cell Transplantation, Conditioning and Multiple Myeloma, sponsored by Nanfang Hospital, Southern Medical University. Status unknown at 1 site in China. Open to participants aged 14 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-02-25.
Sponsored by Nanfang Hospital, Southern Medical University · Phase 2/3, Interventional, and Treatment
The purpose of this study is to evaluate the safety and efficacy of Melphalan and BUCY+VP-16 myeloablative conditioning regimens in multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
3,760 studies on the registry are indexed under Multiple Myeloma; 769 are open to participants now.
This study's planned enrollment of 122 is above the median of 41 across 3,005 interventional studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Nanfang Hospital, Southern Medical University is the lead sponsor of 490 studies on the registry; 214 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For MM patients undergoing auto-HSCT，BUCY+VP-16 conditioning regimen was BU 3.2 mg/kg/day on days -8 and -6；CY 60 mg/kg/day on days -5 and -4; VP-16 10mg/kg/day on days -3 and -2.
Drug: Busulfan (BU) · Drug: Cyclophosphamide (CY) · Drug: Etoposide (VP-16)
For MM patients undergoing auto-HSCT，Melphalan conditioning regimen was Melphalan 200mg/m2 on day -2.
Drug: Melphalan
Busulfan was administered at 3.2 mg/kg/day on days -8 to -6. -7 to -4.
Cyclophosphamide was administered at 60 mg/kg/day on days -5 to -4. on days -3 to -2.
Etoposide was administered at 10 mg/kg/day on days -3 to -2. -3 to -2.
Melphalan was administered at 200mg/m2 on day -2.
OS
overall survival (OS)
Time frame: 3 year
relapse rate relapse rate
relapse rate
Time frame: 3 year
DFS
disease-free survival (DFS)
Time frame: 3 year
TRM
transplant-related mortality (TRM)
Time frame: 3 year
Started Jan 2018 (actual). Primary completion is estimated for Dec 2020, 35 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Busulfan · Cyclophosphamide · Etoposide
Nanfang Hospital, Southern Medical University →